MYNZ
Mainz Biomed N.V.
stock NASDAQ

Quantum Cyber N.V. (QUCY) had a massive move Wednesday on a corporate-pivot announcement. This one is more interesting than your typical small-cap headline trade — there's an actual transformation story behind the ticker.
\*\*The catalyst\*\*
QUCY announced an exclusive IP License Agreement with Miami-based BP United Inc. for an autonomous "sky defense" platform — 25+ km range, autonomous takeoff, navigation and landing, encrypted comms, designed for surveillance, interdiction and payload delivery. CFO Bill Caragol described the deal as securing both an exclusive IP position and a commercial supply chain in a single transaction. Backdrop is a proposed FY27 budget allocation of around $55B for autonomous warfare programs, up from roughly $225M previously.
\*\*Why QUCY specifically\*\*
This is the story most retail probably missed: QUCY is the former Mainz Biomed (ticker MYNZ), a German cancer-diagnostics company. Ticker changed to QUCY on March 12, 2026; the legal name changed to Quantum Cyber N.V. at the April shareholder meeting. The company is winding down its German subsidiary, evaluating a sale of the colorectal-cancer screening assets, and pivoting hard into quantum computing, cybersecurity and now autonomous defense systems. Robert P. Liscouski was brought on as Chairman as part of the rebrand. The "Healthcare / Diagnostics" sector label still showing in screeners is stale — the underlying business is a different company now.
\*\*The numbers\*\*
\- Market cap: \~$4M (yes, single digit millions)
\- Float: \~10.8M shares
\- Day volume: well above the 895K 30-day average by mid-morning
\- Prev close: $0.32
\- Premarket high: $0.65 (+101% from prev close, before the regular session even opened)
\- Gap at open: -2% (premarket gain almost fully retraced before the bell)
\- Short ratio: 0.81
\- Short % of float: 8.5%
\- 52-week range: $0.30 to $2.50 (peak at $1.90 still \~24% below the prior 52-week high)
The whole company is worth less than a Manhattan one-bedroom. That's the kind of cap where a single news cycle reprices the entire equity.
\*\*Signal timing\*\*
I got an alert at 8:26 AM ET at $0.59. The peak printed at $1.90 around 4:26 PM ET — about 8 hours later. +222% on the catchable move. Closed near $1.27 in extended hours, so the stock held a good chunk of the gain rather than full-fading like most premarket pumps.
\*\*Bear case\*\*
\- An IP license is not booked revenue. There's no contract value disclosed and no commercial supply chain yet.
\- The pivot itself is the bull case — but it's also the risk. From cancer diagnostics to quantum computing to autonomous drones inside 60 days is an enormous strategic gap, and execution risk on a $4M-cap company is real.
\- 52-week high was $2.50. The peak printed inside the prior range, which is more sustainable than an extension, but plenty of overhead supply from prior holders.
\- Insider history is worth a look — Mainz Biomed had multiple offerings during its biotech phase. Dilution risk on a nano-cap that just had a triple-digit day is non-trivial.
\- Defense procurement timelines are years, not weeks. Even if the FY27 budget hits the headline number, almost none of it flows to a company with no product yet.
Not financial advice — pivot-stories on nano-cap shells can go either way. Tradable on momentum, dangerous as a hold.
https://preview.redd.it/mbnm6aiy6z0h1.png?width=2779&format=png&auto=webp&s=2a2aad1a5d0085ff83cffa8800f0c9fef29e8a8d

Quantum Cyber N.V. (QUCY) had a massive move Wednesday on a corporate-pivot announcement. This one is more interesting than your typical small-cap headline trade — there's an actual transformation story behind the ticker.
\*\*The catalyst\*\*
QUCY announced an exclusive IP License Agreement with Miami-based BP United Inc. for an autonomous "sky defense" platform — 25+ km range, autonomous takeoff, navigation and landing, encrypted comms, designed for surveillance, interdiction and payload delivery. CFO Bill Caragol described the deal as securing both an exclusive IP position and a commercial supply chain in a single transaction. Backdrop is a proposed FY27 budget allocation of around $55B for autonomous warfare programs, up from roughly $225M previously.
\*\*Why QUCY specifically\*\*
This is the story most retail probably missed: QUCY is the former Mainz Biomed (ticker MYNZ), a German cancer-diagnostics company. Ticker changed to QUCY on March 12, 2026; the legal name changed to Quantum Cyber N.V. at the April shareholder meeting. The company is winding down its German subsidiary, evaluating a sale of the colorectal-cancer screening assets, and pivoting hard into quantum computing, cybersecurity and now autonomous defense systems. Robert P. Liscouski was brought on as Chairman as part of the rebrand. The "Healthcare / Diagnostics" sector label still showing in screeners is stale — the underlying business is a different company now.
\*\*The numbers\*\*
\- Market cap: \~$4M (yes, single digit millions)
\- Float: \~10.8M shares
\- Day volume: well above the 895K 30-day average by mid-morning
\- Prev close: $0.32
\- Premarket high: $0.65 (+101% from prev close, before the regular session even opened)
\- Gap at open: -2% (premarket gain almost fully retraced before the bell)
\- Short ratio: 0.81
\- Short % of float: 8.5%
\- 52-week range: $0.30 to $2.50 (peak at $1.90 still \~24% below the prior 52-week high)
The whole company is worth less than a Manhattan one-bedroom. That's the kind of cap where a single news cycle reprices the entire equity.
\*\*Signal timing\*\*
I got an alert at 8:26 AM ET at $0.59. The peak printed at $1.90 around 4:26 PM ET — about 8 hours later. +222% on the catchable move. Closed near $1.27 in extended hours, so the stock held a good chunk of the gain rather than full-fading like most premarket pumps.
\*\*Bear case\*\*
\- An IP license is not booked revenue. There's no contract value disclosed and no commercial supply chain yet.
\- The pivot itself is the bull case — but it's also the risk. From cancer diagnostics to quantum computing to autonomous drones inside 60 days is an enormous strategic gap, and execution risk on a $4M-cap company is real.
\- 52-week high was $2.50. The peak printed inside the prior range, which is more sustainable than an extension, but plenty of overhead supply from prior holders.
\- Insider history is worth a look — Mainz Biomed had multiple offerings during its biotech phase. Dilution risk on a nano-cap that just had a triple-digit day is non-trivial.
\- Defense procurement timelines are years, not weeks. Even if the FY27 budget hits the headline number, almost none of it flows to a company with no product yet.
Not financial advice — pivot-stories on nano-cap shells can go either way. Tradable on momentum, dangerous as a hold.
https://preview.redd.it/mbnm6aiy6z0h1.png?width=2779&format=png&auto=webp&s=2a2aad1a5d0085ff83cffa8800f0c9fef29e8a8d